Alnylam Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yvonne L. Greenstreet
- Full Time Employees
- 2,500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 675 West Kendall Street Cambridge MA United States of America 02142
- IPO Date
- Jun 1, 2004
- CIK
- 0001178670
- Website
- alnylam.com
- Similar Companies
- Business
- Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.
Andra AP fonden Raises Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Lifted by Fifth Third Bancorp
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Allspring Global Investments Holdings LLC
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
The Healthcare M&A Wave
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript